Pure MHC, LLC is a discovery and development company with platform technology and expertise in disease-specific (HLA Class I and Class II) target identification and validation, as well as immunotherapeutic drug development for cancer, infectious, and autoimmune diseases. Pure MHC provides collaborative support to researchers in epitope validation, development, and therapeutic exploitation through expansive HLA experience, and expertise in mass spectrometry, proteomics, peptidomics, informatics, tissue culture, epitope screening & validation, peptide binding, HLA extraction, as well as the transfection, production, and purification of the company’s proprietary soluble HLA proteins.
Our mission is to support and enable the creation of novel therapeutics for the treatment of cancer, autoimmune, and infectious disease by leveraging the human leukocyte antigen (HLA) system to selectively identify and eliminate diseased cells.
Pure MHC is a recognized world leader in the HLA system, with well over 100 years of cumulative team experience and thought leadership in the field, and deep domain expertise in antigen discovery, processing, and presentation.
The University of Oklahoma Health Sciences Center has launched a research collaboration with Pure MHC, LLC an innovative biotechnology company, to work toward the development of a vaccine for the COVID-19 virus.
“With OU, we are acquiring the actual COVID-19 virus, and we will infect cells and look for the targets on the infected cells. We will use those targets to either develop a vaccine or to directly target them with something like monoclonal antibodies.”
Director of Immuno-Proteomics for Pure MHC and a graduate of the OU Health Sciences Center.